Tumor antigen vaccine

UbiVac Announces Clinical Trial Collaboration with Bristol Myers Squibb on Combination Immunotherapy for Advanced Triple Negative Breast Cancer

Tuesday, June 9, 2020 - 4:00pm

The Phase 1b multicenter trial will test the hypothesis that combination immunotherapy with the DPV-001 cancer vaccine and anti-OX40 will augment anticancer immunity in patients with advanced triple negative breast cancer.

Key Points: 
  • The Phase 1b multicenter trial will test the hypothesis that combination immunotherapy with the DPV-001 cancer vaccine and anti-OX40 will augment anticancer immunity in patients with advanced triple negative breast cancer.
  • Triple Negative Breast Cancer is negative for estrogen receptors, progesterone receptors and HER2 receptors, and therefore treatment options are limited.
  • We believe that cutting-edge immunotherapy combinations have the potential to induce long-lasting anticancer immunity and translate into clinical responses in patients with triple negative breast cancer.
  • UbiVac is a privately held, clinical stage immunotherapy company engaged in the research and development of therapeutic vaccines to combat cancer.

EpiVax Oncology Inc. Announces It Has Reduced the Timeline of Its Personalized Neoantigen Therapeutic Cancer Vaccine Process to Under Four Weeks

Thursday, March 26, 2020 - 8:42pm

EpiVax Oncology, Inc ., a precision cancer immunotherapy company, today announced it has reduced the timeline from biopsy to vaccine to under 4 weeks for its personalized neoantigen therapeutic cancer vaccines.

Key Points: 
  • EpiVax Oncology, Inc ., a precision cancer immunotherapy company, today announced it has reduced the timeline from biopsy to vaccine to under 4 weeks for its personalized neoantigen therapeutic cancer vaccines.
  • Previously, the process to create an a personalized vaccine starting from tumor biopsy took at least 12 to 18 weeks.
  • With a personalized cancer vaccine process under 4 weeks, we can safely create a vaccine to treat all stages of aggressive cancer including in the neoadjuvant, adjuvant and metastatic setting.
  • EpiVax Oncology's personalized vaccine design platform, Ancer, incorporates the world-class EpiMatrix system and the innovative JanusMatrix tool, which were exclusively licensed to EpiVax Oncology by EpiVax.

Triumvira Immunologics and Lonza Announce Collaboration to Develop Innovative Point-of-Care Manufacturing for TAC T-Cell Therapeutic Targeting Solid Tumors

Tuesday, March 24, 2020 - 11:00am

This collaboration, aimed at the development of Triumvira's TAC01-HER2 T-cell therapy for treating solid tumors, will leverage Lonza's expertise in process development and the usage of its proprietary Cocoon Platform.

Key Points: 
  • This collaboration, aimed at the development of Triumvira's TAC01-HER2 T-cell therapy for treating solid tumors, will leverage Lonza's expertise in process development and the usage of its proprietary Cocoon Platform.
  • Immunotherapy, particularly T-cell products, belong to the most potent drugs that could overcome the complex barriers encountered in solid tumors.
  • The TAC receptor represents a significant advancement, providing a novel mechanism of T-cell activation, leading to improved anti-tumor responses in solid tumor models.
  • Within this collaboration, TAC01-HER2 will initially be tested in a Phase 1/2 clinical trial examining different HER2-overexpressing solid tumors.

Treos Bio Presents Positive Data on Its Off-the-Shelf Shared Antigen-Based Cancer Vaccine Against Microsatellite-stable metastatic colorectal cancer and Personalized Vaccines Against Three Metastatic cancers

Thursday, November 7, 2019 - 12:00pm

PAScal enabled the development of two families of effective shared antigen-based cancer vaccines (off-the-shelf and personalized) that target 19 cancer indications and are commercially scalable, without need for tumor biopsy and on-demand manufacturing.

Key Points: 
  • PAScal enabled the development of two families of effective shared antigen-based cancer vaccines (off-the-shelf and personalized) that target 19 cancer indications and are commercially scalable, without need for tumor biopsy and on-demand manufacturing.
  • Treos Bio uses a knowledgebase and algorithm embedded in its proprietary PASCal tool to develop cancer vaccines.
  • Personalized vaccines administered to three HLA-genotyped metastatic cancer patients (with ovarian-, breast- and colorectal cancer) induced CD8+ T-cell responses against an average of 12 different vaccine antigens, from the 12-13 vaccine peptides administered for each patient.
  • Treos is the first in the immunotherapy field to generate positive data for classically cold tumors: MSS mCRC, ovarian cancer and breast cancer, said Christopher C. Gallen, MD, PhD, and Chairman of Treos Bio.

Personalized gene-edited immune cell therapy for patients with solid cancers: New data establishes approach for verifying patient-specific cancer mutation targets

Sunday, July 21, 2019 - 6:30pm

Each patient's cancer has a private signature of mutations, creating an opportunity to develop fully personalized immune therapies that have the potential to eradicate tumor cells.

Key Points: 
  • Each patient's cancer has a private signature of mutations, creating an opportunity to develop fully personalized immune therapies that have the potential to eradicate tumor cells.
  • Defining these cancer mutation targets for each person, known as neoantigens, enables the company to use its proprietary gene engineering technologies to manufacture an immune cell therapy product for each person with cancer.
  • The company has begun enrolling patients with advanced solid tumors in its Phase 1 dose escalation study of NeoTCR-P1, an autologous gene-edited TCR T cell product that targets personalized neoantigens ( https://clinicaltrials.gov/ct2/show/NCT03970382 ).
  • The company's approach is designed to select and confirm tumor-exclusive mutations to empower a patient's immune system to target their specific cancer.

Elios Therapeutics Announces Positive Top-Line Data from Phase IIb Study Evaluating TLPLDC, a Personalized Therapeutic Cancer Vaccine, in Patients with High-Risk Melanoma

Wednesday, July 17, 2019 - 12:30pm

"As a treating physician, substantially reducing the risk of cancer from returning is a high priority for me and my patients.

Key Points: 
  • "As a treating physician, substantially reducing the risk of cancer from returning is a high priority for me and my patients.
  • "This is the first positive Phase IIb study of a personalized cancer vaccine in patients with high-risk melanoma, an aggressive disease with a need for safer and more effective treatment options," said Buddy Long, chief executive officer of Elios Therapeutics.
  • Melanoma is less common than some other types of skin cancer, but it is more likely to grow and spread.
  • Elios Therapeutics, LLC, is a biopharmaceutical company developing a portfolio of innovative personalized therapeutic cancer vaccines targeting unmet medical needs across a broad range of tumor types.

Pepscan Produces Clinical Peptides for Innovative Personalized Cancer Vaccine Trial

Tuesday, June 25, 2019 - 1:00pm

LELYSTAD, Netherlands, June 25, 2019 /PRNewswire/ --Pepscan has positioned itself as a critical partner in a collaborative clinical trial with personalized anti-cancer vaccines.

Key Points: 
  • LELYSTAD, Netherlands, June 25, 2019 /PRNewswire/ --Pepscan has positioned itself as a critical partner in a collaborative clinical trial with personalized anti-cancer vaccines.
  • In this trial, Pepscan is solely responsible for production of clinical neoantigen peptides, tailored to tumors of individual patients.
  • "Our crucial contribution to this clinical trial establishes us as a key supplier of peptide technologies in the cancer vaccine field."
  • The company offers her expertise to new personalized cancer vaccine initiatives now, contributing to new avenues towards personalized cancer treatment.

Minerva Biotechnologies Announces FDA Acceptance of IND Application for huMNC2-CAR44 T cells to Treat Metastatic Breast Cancer

Monday, June 24, 2019 - 3:01pm

huMNC2-CAR44 targets MUC1* (muk one star), a cleaved form of MUC1 present on over 75% of solid tumor cancer cells.

Key Points: 
  • huMNC2-CAR44 targets MUC1* (muk one star), a cleaved form of MUC1 present on over 75% of solid tumor cancer cells.
  • Minerva intends to commence clinical trials in breast cancer before the end of 2019.
  • We are delighted that we will soon be able to begin human clinical trials for metastatic breast cancer, said Minerva CEO Dr. Cynthia Bamdad.
  • Minervas chimeric antigen receptor (CAR) technology genetically engineers the patients own immune cells to recognize and kill specific types of cancer cells.

OncoSec Announces Collaborative Research Agreement in HER2+ Breast Cancer Evaluating the Use of TAVO™ in Combination with Plasmid DNA Vaccines with a World Leading Academic Medical Center

Wednesday, April 17, 2019 - 1:00pm

"We are eager to expand our immunotherapy research in breast cancer through this collaboration with OncoSec.

Key Points: 
  • "We are eager to expand our immunotherapy research in breast cancer through this collaboration with OncoSec.
  • We have previously demonstrated, in a variety of breast cancer models, that local delivery of IL-12 stimulates an anti-breast cancer immune response with applicability beyond end-stage cancer.
  • This delivery system has the potential to be a foundational therapeutic in the treatment of early-stage disease," said Dr. Lyerly.
  • Duke University investigators will conduct preclinical studies using plasmid vaccines targeting HER2 in combination with plasmid vaccines and TAVO in a newly developed endogenous mouse model of HER2+ breast cancer.

The Global Cancer Immunotherapy Market size is expected to reach $128.3 billion by 2024, rising at a market growth of 14.3% CAGR during the forecast period

Wednesday, January 9, 2019 - 12:06am

NEW YORK, Jan. 8, 2019 /PRNewswire/ -- The Global Cancer Immunotherapy Market size is expected to reach $128.3 billion by 2024, rising at a market growth of 14.3% CAGR during the forecast period.

Key Points: 
  • NEW YORK, Jan. 8, 2019 /PRNewswire/ -- The Global Cancer Immunotherapy Market size is expected to reach $128.3 billion by 2024, rising at a market growth of 14.3% CAGR during the forecast period.
  • Cancer immunotherapy is the type of cancer treatment helping the immune system fight cancer.
  • Growing patient population that is suffering from different types of cancer such as lung cancer, breast cancer, ovarian cancer, and other cancers are the factors that drive the global cancer immunotherapy market.
  • Based on application, the market is segmented into Lung cancer, Breast cancer, Colorectal, Prostate cancer, Head & Neck cancer and other application.